Growth Metrics

Femasys (FEMY) Convertible Debt (2023 - 2025)

Femasys posted quarterly Convertible Debt of $3.2 million for Q4 2025, down 37.28% on a QoQ basis from $5.1 million in Q3 2024.

Femasys (FEMY) has 3 years of Convertible Debt data on file, last reported at $3.2 million in Q4 2025.

  • For the quarter ending Q4 2025, Convertible Debt changed N/A year-over-year to $3.2 million; the trailing twelve-month figure through Dec 2025 stood at $3.2 million (changed N/A YoY), and the FY2025 full-year result was $3.2 million, changed N/A from the prior year.
  • Convertible Debt for Q4 2025 stood at $3.2 million, down from $5.1 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $5.1 million in Q3 2024 and bottomed at $3.2 million in Q4 2025.
  • The 3-year median for Convertible Debt is $4.5 million (2024), against an average of $4.3 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Femasys 22.30 Mn 16.91 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 3.18 Mn
Sep 30, 2024 5.07 Mn
Jun 30, 2024 4.76 Mn
Mar 31, 2024 4.47 Mn
Dec 31, 2023 4.26 Mn